Kidney Week

Abstract: TH-PO846

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitor in Diabetic Kidney Transplant Recipients: A Case-Control Study

Session Information

• Transplantation: Clinical - I
  November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Transplantation

• 2102 Transplantation: Clinical

Authors

• Ibrahim, Ashraf Ahmed Fawzy, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar

Ashraf Ahmed Fawzy Ibrahim,

• Ali, Mohamed Yousif Mohamed Salih, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar

Mohamed Yousif Mohamed Salih Ali,

• Mahgoub, Ali, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar

Ali Mahgoub,

• Mohamed Abdul Rahman, Rasha, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar

Rasha Mohamed Abdul Rahman,

• Abdelhalim, Mohamed, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar

Mohamed Abdelhalim,

• Hamdi, Ahmed Farouk, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar

Ahmed Farouk Hamdi,

• Ghonimi, Tarek Abdellatif, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar

Tarek Abdellatif Ghonimi,

• Fouda, Tarek Ahmed, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar

Tarek Ahmed Fouda,

• Hussain, Mohammed Ezzat, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar

Mohammed Ezzat Hussain,

• Elshirbeny, Mostafa, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar

Mostafa Elshirbeny,

• Eltayeb, Fatima Babiker ahmed, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar

Fatima Babiker ahmed Eltayeb,

• Elgaali, Musab, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar

Musab Elgaali,

• Arroub, Shaimaa Ahmad, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar

Shaimaa Ahmad Arroub,

• Ibrahim, Rania Abdelaziz, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar

Rania Abdelaziz Ibrahim,

• Abuhelaiqa, Essa, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar

Essa Abuhelaiqa,

• Hamad, Abdullah Ibrahim, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar

Abdullah Ibrahim Hamad,

• Al-Malki, Hassan A., Hamad Medical Corporation, Doha, Ad Dawhah, Qatar

Hassan A. Al-Malki,

• Alkadi, Mohamad M., Hamad Medical Corporation, Doha, Ad Dawhah, Qatar

Mohamad M. Alkadi,

Background

KDIGO guidelines recommend initiating sodium-glucose cotransporter 2 inhibitors (SGLT2i) in diabetic chronic kidney disease (CKD) patients for its cardiovascular and renal protective effects. However, up till now, there are no recommendations regarding its use in diabetic kidney transplant recipients (KTR). The aim of this study was to determine the efficacy and safety of SGLT2i in diabetic KTR.

Methods

This was a retrospective case-control study. Cases (diabetic KTR using SGLT2i) and controls (diabetic KTR not using SGLT2i) were matched for recipient age, gender, year of transplant, and donor type.
This study has been approved by Hamad general hospital research center. MRC-01-23-077

Results

There were 78 cases and 78 controls. The mean follow-up period in cases and controls was 23.9 and 24.1 months, respectively. Both groups had similar baseline graft function and HbA1c. Compared to controls, cases had a statistically significant reduction of BMI (-1.1 vs. +0.23; P<0.001). There was also a trend for better graft function and diabetes control, but it did not reach statistical significance. Both groups had similar adverse events such as AKI, UTI, cardiovascular and cerebrovascular complications (figure 1).

Conclusion

SGLT2i use in diabetic KTR was associated with a significant reduction in BMI and a trend for better kidney function and diabetes control. Longer prospective randomized controlled trials are needed to confirm their safety and efficacy outcomes in KTR.

Funding

• Government Support – Non-U.S.